Moderna, Inc.

🇺🇸NASDAQ Global Select

Articles

60
Show Summary
Show Bulletpoints
Detailed View
Bullish +55

Moderna Is Up 14% Today: Is It Outperforming Other Vaccine Stocks Like Merck and Pfizer?

📈 Moderna shares hit new 52-week high of $69.29.

💰 Q1 revenue surged 264% to $389 million, beating estimates.

🏥 FDA unanimously endorsed flu vaccine mFlusiva for adults 50+.

⏳ August 5, 2026 FDA decision on mRNA-1010 is key.

🎯 Company targets 2028 break-even while expanding oncology therapies.

📈 Moderna shares jumped 14% to $68, hitting a new 52-week high of $69.29 in Friday afternoon trading.

🏥 The FDA advisory committee unanimously endorsed Moderna's flu vaccine mFlusiva for adults 50 and older.

💰 Q1 2026 revenue reached $389 million, a 264% year-over-year increase that beat consensus by 65%.

📅 The company reaffirmed guidance for up to 10% revenue growth in 2026 in its latest 10-Q filing.

🎯 Moderna aims for a 2028 break-even goal while expanding into oncology and autoimmune disease therapies.

📉 Pfizer's Comirnaty revenue fell 59% to $232 million, highlighting reliance on non-COVID portfolios.

📊 Moderna stock is up 45% over the past month compared to Merck's 7% gain and Pfizer's 6% loss.

💸 The consensus analyst price target sits at $43.45, significantly below today's trading price of $68.

📉 Recent insider transactions show a net selling trend with 75 recent deals tilting toward sales.

⏳ The next major catalyst is the August 5, 2026 FDA decision on mRNA-1010 approval.

🔬 Upcoming Phase 3 readouts for norovirus, intismeran in melanoma, and propionic acidemia are being watched.

🏦 Jefferies raised its price target to $53 while maintaining a Hold rating on the stock.

Bullish Signals
  • Shares surged 14% to new 52-week high of $69.29.
  • FDA unanimously endorsed flu vaccine mFlusiva for adults 50+.
  • Q1 2026 revenue jumped 264% YoY to $389 million.
  • Company reaffirmed up to 10% revenue growth guidance for 2026.
  • Stock gained 45% this month while peers lagged behind.
Risk Factors
  • Analyst target $43.45 is well below current price of $68.
  • Stock trades at forward P/E of 23x on uncertain earnings.
  • Recent insider net selling trend with 75 recent sales deals.
  • Leerink target near $24 and Morgan Stanley near $33.
  • Pfizer revenue fell 59% to $232 million in Q1 2026.
  • Consensus cautious with 16 Hold ratings against Buys and Sells.
Bullish Signals
  • Moderna shares surged 14% to hit a new 52-week high of $69.29, significantly outperforming peers Merck and Pfizer.
  • The FDA advisory committee unanimously endorsed Moderna's flu vaccine mFlusiva for adults 50 and older.
  • Q1 2026 revenue jumped 264% year-over-year to $389 million, beating consensus estimates by 65%.
  • Moderna reaffirmed guidance for up to 10% revenue growth in 2026 based on its recent 10-Q filing.
  • The company is advancing a diverse pipeline including T-cell engagers, an in-vivo CAR-T program, and a personalized cancer vaccine.
  • Moderna stock has gained 45% over the past month while Merck added only 7% and Pfizer fell 6%.
  • Year-to-date performance shows Moderna up 130% against Merck's 21% gain and Pfizer's 3% decline.
  • Jefferies analyst raised its price target to $53, signaling continued interest in the company's potential.
Risk Factors
  • The consensus analyst price target is $43.45, which is well below the current trading price of $68.
  • Moderna stock trades at a forward P/E ratio of 23x on still-uncertain forward earnings.
  • Recent insider transactions show a net selling trend with 75 recent deals tilting toward sales.
  • Leerink has a price target near $24 and Morgan Stanley near $33, indicating the stock is running ahead of Street positioning.
  • Pfizer's Comirnaty revenue fell 59% to $232 million in Q1 2026, underscoring reliance on non-COVID portfolios.
  • The sell-side consensus remains cautious with 16 Hold ratings against a smaller cluster of Buys and Sells.
Bullish +65

MRNA Stock Jumps As FDA Backs Flu Shot And Expansion Plans - StocksToTrade

📈 Moderna stock rose 6.21% to $63.08 on positive regulatory news.

✅ FDA voted unanimously for mRNA-1010 flu vaccine in adults 50+.

💰 Revenue hit $389M quarterly with $5.2B cash against $4.08B liabilities.

🔄 Restructuring supports vaccines, oncology, and rare disease launches by 2027–2028.

🇩🇪 Company invests in German manufacturing sites to expand European footprint.

📈 Moderna stock jumped 6.21% on Tuesday, June 23, 2026, rising from a low of $58.70 to close near $63.08 following positive regulatory and corporate news.

✅ The FDA advisory committee voted unanimously (9-0) that the mRNA-1010/mFLUSIVA flu vaccine has a favorable benefit-risk profile for adults aged 50–64 and 65+.

📅 This regulatory vote supports the Biologics License Application ahead of the August 5, 2026 PDUFA deadline for full approval in the U.S.

💰 Moderna reported quarterly revenue of $389M with trailing revenue of $1.94B, though it posted a net loss of $1.34B and EBITDA of -$1.28B.

🛡️ The company holds a strong balance sheet with $5.2B in cash, equivalents, and short-term investments against total liabilities of $4.08B.

🔄 Management announced a restructuring to support three commercial franchises preparing for launches in vaccines, oncology, and rare diseases in 2027–2028.

🇩🇪 Moderna plans to invest in German manufacturing sites, including facilities previously operated by BioNTech, to expand its European footprint.

📉 Analyst Jefferies reiterated a Hold rating with a $45 price target, estimating U.S. flu and combo sales could reach roughly $750M by 2030.

🔬 The upcoming June 25, 2026 Investor Science Day will feature new programs combining mRNA technology with AI and robotics for flu, oncology, and rare disease.

📊 Gross margins stand at 22.6% while EBIT margins are -140%, reflecting heavy R&D and operating spend despite the strengthening stock chart.

Bullish Signals
  • FDA voted 9-0 to support Moderna's flu vaccine, reducing regulatory risk.
  • Stock surged 34% from $47 to $63, showing strong investor confidence.
  • Company holds $5.2B cash against $4.08B liabilities for ample liquidity.
  • New three-franchise model signals strategic shift beyond the COVID one-hit-wonder.
  • German manufacturing expansion builds independent global capacity for future vaccines.
Risk Factors
  • Quarterly net income loss of -$1.34B.
  • Gross margins low at 22.6%.
  • EBIT margins negative at -140%.
  • Free cash flow loss of -$692M.
Bullish Signals
  • The FDA advisory committee voted unanimously (9-0) to support Moderna's mRNA-1010/mFLUSIVA flu vaccine, significantly reducing regulatory risk for the upcoming PDUFA deadline.
  • Moderna's stock price surged over 34% in less than a month, climbing from $47 to $63, indicating strong investor confidence in the company's strategic pivot.
  • The company possesses a substantial cash cushion of $5.2B against $4.08B in total liabilities, providing ample liquidity to fund restructuring and expansion without immediate distress.
  • Management's announcement of a new three-franchise operating model signals a clear strategic shift away from being a one-hit-wonder post-COVID company.
  • Expansion into German manufacturing sites demonstrates a commitment to building independent global capacity ahead of a broader product wave in vaccines and oncology.
Risk Factors
  • Moderna continues to operate at a significant loss with quarterly net income from continuing operations at -$1.34B and EBITDA of -$1.28B.
  • Gross margins are low at 22.6% and EBIT margins are steeply negative at -140%, reflecting heavy ongoing R&D and operating expenditures that pressure profitability.
  • Free cash flow remains negative at approximately -$692M for the quarter, indicating continued high burn rates despite strong cash reserves.
Slightly Bullish +15

Moderna (MRNA) Stock Price, Quote, Charts & News - Invezz

🧬 Moderna develops mRNA medicines for infectious diseases, oncology, and rare disorders.

📉 64% of analysts rate the stock as a Hold.

💸 Insiders net sold $6.2M in stock over the last 90 days.

📈 Technical signals show strong bullish momentum above key moving averages.

🚀 MACD and RSI indicators support a positive long-term trend.

🧬 Moderna utilizes mRNA technology to develop medicines for infectious diseases, oncology, and rare genetic disorders.

📉 Analyst sentiment is mixed with 64% of analysts currently rating the stock as a Hold.

💸 Insiders were net sellers of approximately $6.2M in Moderna stock over the last 90 days.

📈 Technical signals are strongly bullish with the price trading above key moving averages.

🚀 MACD momentum and RSI indicators currently support a positive long-term trend for the stock.

Bullish Signals
  • Stock trades above 50-day and 200-day moving averages.
Risk Factors
  • 64% of analysts rate stock as Hold.
  • $6.2M net insider sales in last 90 days.
  • No recent insider purchases recorded.
Bullish Signals
  • Technical indicators show strong bullish momentum, with the stock price trading above both the 50-day and 200-day moving averages.
  • MACD momentum is supportive, indicating continued upward pressure on the share price.
  • The Relative Strength Index (RSI) is currently in a bullish configuration, suggesting positive market sentiment.
Risk Factors
  • Analyst sentiment is mixed, with a majority of analysts (64%) rating the stock as a Hold rather than Buy.
  • Insider selling has been the main negative factor, with net sales of approximately $6.2M recorded over the last 90 days.
  • No meaningful insider purchases were recorded recently, which may signal a lack of confidence from company insiders.
Bullish +65

Moderna mRNA Flu Vaccine Wins FDA Advisory Committee Backing

📈 FDA advisory committee recommends Moderna mRNA flu vaccine.

🔄 FDA reverses prior controversial decisions under previous leadership.

🧬 Recommendation validates Moderna's mRNA technology platform.

📅 UniQure Huntington's gene therapy approved days earlier.

⚖️ Rapid reversal significant for biotech investors after lengthy trial demands.

📈 Moderna Inc.'s mRNA influenza vaccine was recommended for approval by an FDA advisory committee.

🔄 This vote signals a major turnaround at the FDA, which is reportedly backing off from controversial decisions made under previous leadership.

🧬 The recommendation validates the company's mRNA technology platform despite prior contentious history with the agency.

📅 Recent context includes UniQure NV receiving approval for Huntington's disease gene therapy just days after the Moderna vote.

⚖️ The FDA previously recommended lengthy new trials for similar therapies, making this rapid reversal significant for biotech investors.

Bullish Signals
  • FDA advisory committee recommends approval for Moderna's mRNA flu vaccine.
  • Favorable FDA stance shift eases future regulatory hurdles for Moderna.
  • Resolves previous contentious issues surrounding Moderna's flu vaccine product.
Bullish Signals
  • Moderna Inc. has secured a major regulatory victory with an FDA advisory committee recommending approval for its mRNA flu vaccine.
  • The vote indicates a favorable shift in the FDA's stance on Moderna's technology platform, potentially easing future regulatory hurdles.
  • This development resolves previous contentious issues surrounding the company's flu vaccine product line.
Bullish +72

Moderna Stock Surges As Federal Health Regulators Clear Milestone Older Adult Flu Vaccine Data - TIKR.com

📈 Moderna stock rises after FDA documents support mFlusiva for adults 65+.

🔄 FDA reverses rejection following Moderna's trial design amendment for older adults.

🗓️ Advisory panel votes on mFlusiva; final decision expected by August 5.

💉 Approval would make mFlusiva the first mRNA seasonal flu vaccine in US.

⚠️ FDA notes study limitations including single-season data and excluded frail patients.

📈 Moderna stock surges for a fifth straight day after FDA staff reviewers publish briefing documents suggesting mFlusiva flu shot data supports effectiveness in adults 65 and older.

🔄 The FDA reversed its initial rejection of the flu vaccine application after Moderna agreed to amend its trial design regarding the control arm for patients 65 and over.

🗓️ An independent advisory panel will vote on mFlusiva benefits versus risks for adults 50 and older, with a final FDA decision expected by August 5.

💉 If approved, mFlusiva would become the first mRNA-based seasonal flu vaccine in the United States.

📊 Jefferies analyst Andrew Tsai projects $750 million in combined U.S. flu and COVID-flu combo vaccine sales by 2030.

⚠️ FDA staff noted limitations including study during only one flu season and exclusion of immunocompromised or very frail older adults from trials.

🔬 Moderna agreed to run an additional study in the 65-plus age group if approval is granted for that population.

🌍 The company recently received EU approval for mCOMBRIAX, its flu-plus-COVID combination vaccine, marking the first of its kind globally.

👩‍💼 Moderna appointed Ester Banque as new Chief Commercial Officer to lead upcoming product launches globally.

🚀 Investors are optimistic about a multi-product future with potential pivotal data readouts for cancer therapy Intismeran and rare disease programs expected in 2026.

Bullish Signals
  • FDA documents suggest favorable review of mFlusiva flu vaccine.
  • Moderna reversed FDA rejection after amending trial design.
  • mFlusiva would be first mRNA-based seasonal flu vaccine in US.
  • Jefferies projects $750 million combined sales by 2030.
  • EU approved mCOMBRIAX, first global flu-plus-COVID combo vaccine.
  • Ester Banque appointed Chief Commercial Officer for launches.
  • Pivotal cancer and rare disease data expected in 2026.
Risk Factors
  • Limited to one flu season study.
  • Excluded immunocompromised and frail older adults.
  • FDA notes trial design and population limits.
Bullish Signals
  • Moderna stock has gained meaningfully over five trading sessions following the publication of FDA briefing documents that suggest a favorable review of its mFlusiva flu vaccine.
  • The FDA reversed its initial rejection of the flu vaccine application after Moderna amended its trial design, signaling a positive shift in regulatory stance.
  • Approval of mFlusiva would establish it as the first mRNA-based seasonal flu vaccine in the United States, creating a unique market position.
  • Analyst Andrew Tsai from Jefferies projects $750 million in combined U.S. sales for flu and COVID-flu combo vaccines by 2030.
  • Moderna recently secured EU approval for mCOMBRIAX, becoming the first company globally to receive approval for a flu-plus-COVID combination vaccine.
  • The appointment of Ester Banque as Chief Commercial Officer strengthens the company's leadership team for upcoming global product launches.
  • Future pivotal data readouts for cancer therapy Intismeran and rare disease programs are expected in 2026, suggesting a robust pipeline beyond vaccines.
Risk Factors
  • The mFlusiva vaccine has only been studied during one flu season, which may limit the generalizability of its effectiveness data.
  • Immunocompromised and very frail older adults were excluded from the trials for mFlusiva, leaving efficacy in these high-risk groups unproven.
  • The FDA briefing documents explicitly note limitations regarding the trial design and patient population included in the current data.
Somewhat Bullish +50

Moderna Is Up 94% This Year: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax? - 24/7 Wall St.

📈 Moderna stock rose 9%, extending a 94% year-to-date gain.

✅ EU approved mCOMBRIAX, the world's first flu-plus-COVID vaccine.

⚖️ Q1 2026 GAAP loss widened to $1.34 billion due to charges.

📉 Wall Street holds a 'Reduce' rating with a $37 price target.

🔍 FDA advisory vote on mFlusiva scheduled for June 18.

📈 Moderna stock jumped 9% today, extending a 94% year-to-date gain and outperforming peers Pfizer (+4%) and Novavax (+41%).

🏗️ The company announced a leadership restructuring to prepare for up to three product launches by 2027-2028, including flu-plus-COVID and norovirus vaccines.

✅ EU approval was granted for mCOMBRIAX, the world's first flu-plus-COVID combination vaccine, reinforcing the commercialization narrative.

📅 A critical PDUFA decision for the seasonal flu candidate mRNA-1010 is scheduled for August 5.

⚖️ Q1 2026 included an $878 million non-recurring litigation charge tied to the Arbutus/Genevant patent settlement.

📉 Wall Street maintains a cautious outlook with an average one-year price target of $37 and a consensus 'Reduce' rating.

🔍 An FDA advisory committee vote on mFlusiva for adults 50+ is scheduled for June 18, serving as a key near-term catalyst.

📊 Moderna's Q1 2026 GAAP loss widened to $1.34 billion due to the litigation charge and declining revenue from Comirnaty (-59%) and Paxlovid (-63%).

Bullish Signals
  • Moderna stock up 94% YTD, beating rivals.
  • Leadership shift targets commercial scale by 2027-2028.
  • EU approved mCOMBRIAX; mRNA-1010 PDUFA Aug 5.
  • Pipeline diversifies with flu-COVID combo and norovirus vaccines.
Risk Factors
  • Q1 2026: $878M non-recurring litigation charge recorded.
  • Comirnaty revenue down 59%; Paxlovid down 63% YoY.
  • Widened GAAP loss of $1.34 billion in Q1 2026.
  • Analysts rate 'Reduce' with average price target of $37.
  • Stock down 74% from pandemic-era peak highs.
Bullish Signals
  • Moderna stock has delivered a remarkable 94% return year-to-date, significantly outperforming major vaccine competitors Pfizer and Novavax.
  • The leadership restructuring signals a strategic shift toward commercial scale, preparing the company for multiple product launches in 2027-2028.
  • Regulatory momentum is strong with recent EU approval for mCOMBRIAX and an upcoming PDUFA decision for mRNA-1010 on August 5.
  • The pipeline includes diverse candidates such as a flu-plus-COVID combo vaccine, seasonal flu vaccine, and norovirus vaccine, diversifying future revenue streams.
Risk Factors
  • Moderna recorded a $878 million non-recurring litigation charge in Q1 2026 related to the Arbutus/Genevant patent settlement.
  • Revenue from key products is declining, with Comirnaty down 59% and Paxlovid down 63% year-over-year in Q1 2026.
  • The company reported a widened GAAP loss of $1.34 billion for the first quarter of 2026.
  • Analyst consensus remains cautious with an average one-year price target of $37 and a 'Reduce' rating.
  • The stock is still down 74% from its pandemic-era peaks, indicating significant downside from historical highs.
Somewhat Bullish +50

Moderna Launches Moderna Direct with “eCommerce Powered by FFF Enterprises™”

🚀 Moderna launches "Moderna Direct" platform for streamlined healthcare product access.

🤝 Solution powered by FFF Enterprises' proprietary BioSupply® e-commerce technology.

🎨 Customized branded experience enhances ordering process and customer innovation.

🔄 Enables direct-to-healthcare models bypassing traditional distribution channels.

📞 Contact Michelle Valenzuela at FFF for service inquiries.

🚀 Moderna has launched a new direct-to-customer platform called "Moderna Direct" to streamline product access for healthcare customers.

🤝 The platform is powered by FFF Enterprises, Inc., a specialty pharmaceutical distributor based in Temecula, California.

💻 The solution utilizes BioSupply®, which is FFF's proprietary e-commerce platform built on a scalable foundation.

🎨 The new site features a customized, Moderna-branded experience designed to enhance the ordering process for customers.

🗣️ Robert Keith, SVP of customer experience at FFF, stated that the collaboration allows them to build on a strong foundation to elevate the customer experience.

🚀 Matt Block, U.S. general manager at Moderna, described the launch as an important step forward in supporting their customers and driving future innovation.

🏢 FFF Enterprises has been operating since 1988 and is a privately held, multibillion-dollar healthcare technology company.

🔄 The new platform enables direct-to-healthcare business models that bypass traditional distribution channels for manufacturing partners.

🛡️ FFF's nationwide commerce network utilizes world-class technology and cybersecurity solutions to support its partners.

📞 For inquiries regarding the e-commerce services, interested parties should contact Michelle Valenzuela, VP of marketing & communications at FFF.

Bullish Signals
  • Moderna selected FFF Enterprises' BioSupply® platform for its new Direct site.
  • Launch supports customers and drives innovation in Moderna's direct business model.
  • FFF brings 38 years of growth with scalable, intuitive interface enhancements.
  • Moderna Direct offers streamlined access via a customized, branded experience.
  • Partnership leverages world-class tech, cybersecurity, and nationwide distribution networks.
Bullish Signals
  • Moderna has selected FFF Enterprises' proprietary BioSupply® ecommerce platform to power its new Moderna Direct site, enhancing the ordering experience for customers.
  • The launch represents an important step forward in supporting customers and creates momentum for future innovation within Moderna's direct business model.
  • FFF Enterprises brings 38 years of growth and a strong, scalable foundation to this collaboration, ensuring intuitive interface enhancements and expanded self-service capabilities.
  • Moderna Direct provides streamlined access to the product portfolio through a customized, Moderna-branded experience that bypasses traditional channels.
  • The partnership leverages world-class technology and cybersecurity solutions supported by a nationwide network of distribution and infusion pharmacy locations.
Risk Factors
  • No negative aspects or risks identified in the provided article; it is a positive press release announcing a new partnership and platform launch.
Slightly Bullish +15

Flagship Pioneering trades 9,263 Moderna (MRNA) shares via option exercise - Stock Titan

📅 Flagship Pioneering exercised options for 9,263 Moderna shares on May 21, 2026.

💰 Shares were immediately sold at $46.84 per share for a net profit of $27.69.

👤 Noubar Afeyan controls entities holding over 2 million direct and 4.6 million indirect shares.

⚖️ Afeyan disclaims full beneficial ownership, retaining interest only via his pecuniary stake.

📅 On May 21, 2026, Flagship Pioneering exercised options for 9,263 Moderna shares at $19.15 per share.

💰 The same entity immediately sold those 9,263 shares on the open market at an average price of $46.84 per share.

👤 Noubar Afeyan is the ultimate control person of the reporting entities and holds over 2 million direct shares.

🏦 Related Flagship Ventures funds hold additional indirect stakes totaling approximately 4.6 million shares combined.

📉 The transaction resulted in a net profit per share of roughly $27.69 before fees due to the spread between exercise and sale prices.

⚖️ Afeyan disclaims full beneficial ownership of Flagship entity holdings, retaining interest only to the extent of his pecuniary stake.

Bullish Signals
  • Insider sold at $46.84 premium vs $19.15 strike.
  • Noubar Afeyan owns over 2.2 million shares directly.
  • Matched exercise-and-sell is neutral liquidity, not distress.
Risk Factors
  • Sale of 9,263 shares increases supply and may lower price.
  • Afeyan's limited disclosure reduces visibility into his total exposure.
Bullish Signals
  • The insider sold shares at a significant premium to the option strike price ($46.84 vs $19.15), suggesting confidence in the stock's value relative to the cost basis.
  • Noubar Afeyan maintains substantial direct ownership of over 2.2 million shares, indicating continued skin in the game despite the sale activity.
  • The matched exercise-and-sell transaction is a neutral liquidity event rather than a signal of distress or lack of conviction.
Risk Factors
  • The open-market sale of 9,263 shares increases immediate supply, which can exert short-term downward pressure on the stock price.
  • Afeyan's disclaimer of beneficial ownership for Flagship entity holdings limits transparency regarding his total economic exposure to the company.
Slightly Bullish +25

FDA to Hold Review Meeting for Moderna's Flu Vaccine

🩺 FDA reviews Moderna's experimental mRNA flu vaccine at a June 18 advisory meeting.

⏳ Approval is required before standalone distribution can begin in August.

🔄 The agency reverses a February rejection following earlier regulatory objections.

🧬 Mflusiva marks the first influenza vaccine developed using mRNA technology.

🩺 The FDA has scheduled a public advisory committee meeting for June 18 to review Moderna's experimental flu vaccine, Mflusiva.

🔬 This gathering will feature independent scientific and public-health experts evaluating the vaccine's safety and effectiveness.

⏳ Moderna is awaiting regulatory approval to begin standalone distribution of this flu shot later this August.

🔄 The agency reversed a February rejection of Mflusiva after initial objections from then-acting FDA vaccines chief Vinay Prasad.

📉 Moderna's stock prices have dropped significantly due to declining demand for its pandemic-era Spikevax product.

🧬 Mflusiva will be the first influenza vaccine developed using mRNA technology, a format currently criticized by HHS Secretary Robert F. Kennedy Jr.

Bullish Signals
  • FDA meeting scheduled June 18 for Mflusiva review.
  • Agency pivoted from February rejection to convene scientific review.
  • Moderna positioned for standalone flu approval by late August.
  • Mflusiva would be the first mRNA flu vaccine.
Risk Factors
  • FDA rejected initial standalone flu shot application due to Vinay Prasad.
  • HHS Secretary RFK Jr. criticizes mRNA technology and oversees FDA.
  • Moderna stock dropped from pandemic highs amid falling Spikevax demand.
  • August regulatory approval critical; June 18 meeting could delay timeline.
Bullish Signals
  • The FDA has scheduled a public advisory committee meeting for June 18 to review Moderna's experimental influenza vaccine, Mflusiva.
  • After an initial rejection in February due to objections from the vaccines chief, the agency pivoted and agreed to convene this scientific review.
  • Moderna is positioned to receive standalone flu shot approval later this August if the review is successful.
  • Mflusiva would be the first flu vaccine made with mRNA technology, offering a new technological platform for the company.
Risk Factors
  • Moderna's initial application for its standalone flu shot was rejected in February at the behest of Vinay Prasad, the FDA's vaccines chief, indicating significant regulatory hurdles ahead.
  • The proposed Mflusiva vaccine faces criticism from Health and Human Services Secretary Robert F. Kennedy Jr., who oversees the FDA and has publicly criticized mRNA technology.
  • Moderna's stock has already tumbled from pandemic-era highs due to falling demand for Spikevax, adding pressure before this new product launch.
  • The company is facing a critical dependency on regulatory approval later in August, with the upcoming June 18 advisory committee meeting being a potential bottleneck that could delay or jeopardize the timeline.
Bullish +60

Forget Moderna: This Biotech Juggernaut Is a Way Better Buy Right Now - 24/7 Wall St.

📉 Moderna 2025 revenue collapsed 40% to $1.94 billion.

💸 Moderna cash projected to fall to $4.5B–$5.0B by 2026.

📈 Gilead Q1 HIV revenue hit $5.03B driven by Biktarvy.

🛡️ Gilead's Biktarvy patent extended to April 2036.

📊 Gilead trades at 15x forward earnings vs Moderna's depressed base.

📉 Moderna's full-year 2025 revenue collapsed to $1.94 billion, representing a roughly 40% drop from the prior year.

💸 Moderna's year-end cash is projected to fall from $8.1 billion at the end of 2025 to between $4.5 billion and $5.0 billion by year-end 2026.

📈 Gilead Sciences generated Q1 2026 HIV franchise revenue of $5.03 billion, a 10% increase driven by Biktarvy sales of $3.36 billion.

💰 Gilead declared a quarterly dividend of $0.82 payable June 29, 2026, and repurchased $419 million of stock in Q1 alone.

🔬 Moderna's upcoming catalysts are binary events like the August 5, 2026 flu vaccine PDUFA rather than steady earnings drivers.

🛡️ Gilead's patent protection on Biktarvy was extended to April 2036, ensuring no major loss of exclusivity for a full decade.

📊 Gilead trades at a forward earnings multiple of 15 with a market cap near $162 billion compared to Moderna's depressed base.

🧬 Gilead's headline EPS loss guidance is an artifact of roughly $11.5 billion in one-time IPR&D charges from acquisitions like Arcellx and Ouro Medicines.

Bullish Signals
  • Q1 free cash flow hit $2.427 billion, up 237% YoY.
  • HIV franchise grew 10% to $5.03 billion in Q1 2026.
  • Offers 2.46% dividend yield and $6.0 billion buyback authorization.
  • Non-GAAP gross margin expanded 200 bps to 87.5%.
  • Strong pipeline with four launches and five Phase 3 updates in 2026.
Risk Factors
  • Single COVID product creates concentration risk outside U.S.
  • No dividend or buybacks while drawing on credit facility.
  • Upcoming catalysts are binary events with high uncertainty.
  • $11.5B one-time charges impact Gilead's reported profitability.
Bullish Signals
  • Gilead Sciences is generating real free cash flow, with Q1 free cash flow hitting $2.427 billion, up 237.08% year over year.
  • Gilead's HIV franchise grew 10% to $5.03 billion in Q1 2026, demonstrating strong recurring revenue potential.
  • Gilead offers tangible shareholder returns via a 2.46% dividend yield and a $6.0 billion buyback authorization.
  • Gilead's non-GAAP product gross margin expanded 200 basis points to 87.5%, indicating operational efficiency.
  • Gilead possesses a strong pipeline with up to four potential launches and five Phase 3 updates anticipated in 2026.
  • Moderna's recent stock surge is attributed to a prior year disaster rather than improved fundamentals, suggesting the bounce may be temporary.
Risk Factors
  • Moderna's entire franchise is effectively a single COVID product, creating concentration risk outside the U.S. market.
  • Moderna has no dividend and no buyback program while actively drawing on its credit facility to manage liquidity.
  • Moderna's upcoming catalysts are binary events with high uncertainty rather than predictable earnings drivers.
  • Gilead's headline EPS loss guidance is driven by roughly $11.5 billion in one-time IPR&D charges from acquisitions, which may impact reported profitability.
Bullish +75

Why TIME ranked Moderna the world's most impactful company in 2026 - Stock Titan

🏆 Ranked #1 on TIME's 2026 World's Most Impactful Companies list.

💉 European approval granted in 2026 for mCOMBRIAX flu/COVID vaccine.

🤝 Expanded partnerships with UK, Canada, and Australia for pandemic readiness.

🔬 mRNA Access program now includes 35 global research institutions.

📅 Celebrated fourth anniversary of Charitable Foundation and released annual report.

🏆 Moderna ranked #1 on TIME's 2026 World's Most Impactful Companies list based on the Upright Project's Net Impact Model.

💉 European regulatory approval granted in 2026 for mCOMBRIAX, a flu plus COVID combination vaccine.

🤝 Strategic partnerships expanded with the UK, Canada, and Australia to boost pandemic preparedness and manufacturing capacity.

🔬 mRNA Access program now includes 35 institutions globally researching vaccines for emerging infectious diseases.

📅 Moderna celebrated the fourth anniversary of its Charitable Foundation and released its fourth annual Impacting Human Health Report.

🧬 CEO Stéphane Bancel emphasized the team's dedication to advancing mRNA science for patients and communities worldwide.

Bullish Signals
  • Moderna ranked #1 on TIME's 2026 list.
  • EU approved mCOMBRIAX flu/COVID single-shot vaccine.
  • Alliances with UK, Canada, Australia show confidence.
  • mRNA Access program grew to 35 institutions.
Bullish Signals
  • Moderna secured the top spot on TIME's prestigious 2026 list, validating its leadership in mRNA technology and societal impact.
  • The European approval of mCOMBRIAX expands Moderna's product portfolio with a novel single-shot combination vaccine for flu and COVID.
  • Strategic alliances with major nations like the UK, Canada, and Australia demonstrate strong government confidence in Moderna's pandemic readiness capabilities.
  • The growth of the mRNA Access program to 35 institutions showcases the company's success in fostering open scientific collaboration for neglected diseases.
Very Bearish -75

Moderna: mRNA Vaccine Is Only Viable In A COVID-Like Situation, Strong Sell

📉 mRNA vaccines struggle with lower durability, side effects, and weak post-pandemic market uptake.

✂️ Commercial setbacks force program cuts and a strategic pivot away from current vaccine portfolios.

⚠️ Analysts rate Moderna "Strong Sell" due to intense competition and uncertain financial upside.

🔬 Traditional competitors outperform in key segments, weakening Moderna's overall competitive position today.

📉 Moderna (MRNA) faces significant commercial setbacks as its mRNA vaccines underperform compared to traditional competitors in post-pandemic markets.

💉 RSV and flu mRNA vaccines are struggling due to lower durability, higher side effects, and weak market uptake.

✂️ These commercial challenges have led to program cuts and a need for strategic pivots within Moderna's vaccine portfolio.

🤝 Combination mRNA vaccines such as mCOMBRIAX show regulatory progress, but commercial success remains uncertain due to ongoing vaccine fatigue.

🧬 Personalized cancer vaccines utilizing mRNA technology may benefit from speed, yet face hurdles in margins, scalability, and regulation that limit financial upside.

📄 The analysis is based on the premise that mRNA vaccines may only be viable in scenarios similar to the recent COVID-19 pandemic conditions.

🏆 Traditional competitors are outperforming Moderna in current market segments, weakening its competitive position in key therapeutic areas.

📊 Previous investment coverage from 2024 highlighted risks regarding the uncertain future of mRNA vaccines in a post-pandemic world.

🔬 The author identifies as a Chemistry PhD and scientist with expertise in biotech data to inform their investment thesis.

⚠️ Analysts recommend a "Strong Sell" rating for Moderna stock given these negative commercial trends and uncertainties.

📅 Article published on May 12, 2026, reflecting current market conditions and sentiment as of that date.

🛡️ Standard disclosures indicate the author holds no position in Moderna stock and receives no compensation beyond Seeking Alpha affiliation.

⚖️ Seeking Alpha's standard disclaimer notes that past performance does not guarantee future results and that this is not formal investment advice.

Bullish Signals
  • Combination mRNA vaccines like mCOMBRIAX have achieved regulatory progress, signaling potential pathway for future development.
  • Personalized cancer vaccines leverage the inherent speed of mRNA technology, offering a distinct advantage for R&D efficiency.
Risk Factors
  • MRNA underperforms in post-pandemic markets.
  • RSV & flu mRNA vaccines have durability issues.
  • mCOMBRIAX faces commercial uncertainty.
  • Personalized cancer vaccines face scalability hurdles.
Bullish Signals
  • Combination mRNA vaccines like mCOMBRIAX have achieved regulatory progress, signaling potential pathway for future development.
  • Personalized cancer vaccines leverage the inherent speed of mRNA technology, offering a distinct advantage for R&D efficiency.
Risk Factors
  • Moderna (MRNA) faces major commercial setbacks as mRNA vaccines underperform against traditional competitors in post-pandemic markets.
  • RSV and flu mRNA vaccines struggle with lower durability, higher side effects, and weak uptake, leading to program cuts and strategic pivots.
  • Combination mRNA vaccines like mCOMBRIAX offer regulatory progress but commercial success remains uncertain amid persistent vaccine fatigue.
  • Personalized cancer vaccines may leverage mRNA speed but face margin, scalability, and regulatory hurdles, limiting their financial upside for MRNA.
Slightly Bullish +20

Moderna Stock Is Surging on Hantavirus Threats. Its Chart Offers a Harsh Dose of Reality. - Barchart

📈 Moderna stock surged 22% after hantavirus cruise ship deaths.

🔬 Company holds early-stage vaccine research with U.S. Army and Korea.

⚠️ No approved hantavirus vaccine exists; Moderna's efforts remain ongoing.

💰 Rally driven by headlines, not comparable multibillion-dollar revenue potential.

📉 Stock remains below $350 pandemic peak despite recent gains.

📈 Moderna stock surged up to 22% in two days following news of a deadly hantavirus cluster on an Atlantic cruise ship.

🦠 The outbreak involved three fatalities and sparked international headlines, causing investors to recall the market dynamics of the 2020 pandemic.

🔬 Moderna holds early-stage research collaborations with the U.S. Army and Korea University for a hantavirus vaccine.

⚠️ There is currently no approved vaccine for hantavirus, and Moderna describes its efforts as 'early-stage and ongoing'.

💰 Investors are buying the headline, but the localized outbreak is unlikely to generate multibillion-dollar revenue streams comparable to COVID-19.

📉 The article warns that without significant acceleration in clinical trial timelines, the current rally may be fleeting.

📊 Moderna's stock has been trading below its pandemic peak of over $350 for nearly two years prior to this recent surge.

Bullish Signals
  • Natural first pick for hantavirus due to strong research.
  • Credible mRNA platform with unique early-stage data vs. peers.
Risk Factors
  • No product available; efforts are early-stage and ongoing.
  • Stock price rose sharply without immediate revenue potential.
  • Localized outbreaks unlikely to match COVID-19 era revenue.
  • Rally may be fleeting if trials do not accelerate.
Bullish Signals
  • Moderna is identified as the 'natural first place to look' for hantavirus plays due to its long-standing research and existing collaborations with the U.S. Army and Korea University.
  • The company possesses a credible mRNA platform specifically positioned for this rodent-borne pathogen, distinguishing it from competitors without such early-stage data.
Risk Factors
  • Moderna explicitly describes its hantavirus vaccine efforts as 'early-stage and ongoing,' meaning no product is currently available for sale.
  • The article highlights a 'classic valuation disconnect' where the stock price has risen sharply despite the lack of immediate revenue potential from this specific threat.
  • Analysts caution that a localized outbreak will likely not generate the massive revenue streams seen during the COVID-19 era, limiting the fundamental upside.
  • The rally is described as potentially 'fleeting' if clinical trial timelines do not accelerate significantly to meet investor expectations.
Slightly Bearish -20

Has The Market Rerated Moderna (MRNA) Too Quickly After Its Recent Share Price Surge? - simplywall.st

📉 DCF model projects negative cash flows through 2027 with intrinsic value of $3.90.

💰 Moderna trades at 8.33x sales, exceeding the calculated fair ratio of 1.56x.

📈 Stock delivered 91.2% return last year despite weaker long-term historical performance.

🧠 Optimistic view cites strong balance sheet and pipeline with potential fair value of $175.

⚠️ Cautious view notes risks around vaccine demand and regulatory scrutiny near current price.

📉 DCF Analysis: A two-stage free cash flow model projects negative cash flows through 2027, implying an intrinsic value of $3.90 versus the current price of $46.71.

💰 Valuation Metrics: Moderna trades at a Price-to-Sales ratio of 8.33x, which aligns with industry peers but exceeds the platform's calculated Fair Ratio of 1.56x.

📈 Recent Performance: The stock has delivered a 91.2% return over the last year and a 51.4% return year-to-date despite weaker long-term historical returns.

🧠 Optimistic Narrative: One investor story frames recent weakness as an overreaction, highlighting a strong balance sheet and a broad mRNA pipeline with a potential fair value of $175.

⚠️ Cautious Narrative: Another perspective views current positives as reflected in the price, citing risks around vaccine demand and regulatory scrutiny with a consensus fair value near $46.10.

🏦 Financial Health: The company is noted for having low debt and a balance sheet that some analysts view as trading below book value.

Bullish Signals
  • 91.2% return over last year.
  • 51.4% gain year-to-date.
  • Strong balance sheet with low debt.
  • Significant mRNA pipeline in trials.
  • P/S ratio of 8.33x vs 10.82x industry avg.
Risk Factors
  • DCF projects $3.2B outflows in 2026 and $1.5B in 2027.
  • Stock overvalued by 1,097% per DCF intrinsic value calculation.
  • Current P/S ratio of 8.33x exceeds fair multiple of 1.56x.
  • Revenue risks from vaccine demand fluctuations and competition.
  • Analyst targets near current price imply limited immediate upside.
Bullish Signals
  • Moderna has delivered exceptional recent performance with a 91.2% return over the last year and a 51.4% gain year-to-date.
  • The company maintains a strong balance sheet characterized by low debt levels.
  • A significant portion of the mRNA pipeline is currently in trials, suggesting future growth potential as earlier investments mature.
  • The stock trades below book value according to one optimistic valuation narrative, indicating assets may be undervalued relative to price.
  • Moderna's Price-to-Sales ratio of 8.33x is competitive and close to the Biotechs industry average of 10.82x.
Risk Factors
  • The Discounted Cash Flow model projects substantial negative free cash flows, estimating outflows of $3.2 billion in 2026 and $1.5 billion in 2027.
  • A DCF-based intrinsic value calculation suggests the stock is overvalued by approximately 1,097% compared to current market prices.
  • The proprietary Fair Ratio analysis indicates the stock is expensive relative to a calculated fair multiple of 1.56x versus the current 8.33x P/S ratio.
  • Risks include potential instability in revenue due to vaccine demand fluctuations, intense competition, and regulatory scrutiny.
  • Analyst consensus price targets sit close to the current share price, implying limited immediate upside from a neutral valuation perspective.
Slightly Bullish +25

Moderna shares rise as investors revisit Q1 results, pipeline milestones, and fresh price-target bumps - Quiver Quantitative

📈 Moderna shares rose 4.6% on strong Q1 results and pipeline news.

💰 Q1 revenue hit $389M, with 80% from international markets.

⚖️ GAAP loss of $1.3B included a $0.9B litigation settlement charge.

✅ EU approved mNEXSPIKE and flu+COVID combo vaccine mCOMBRIAX.

🔬 Phase 3 trial for intismeran in NSCLC officially initiated.

📈 Moderna shares gained 4.6% as investors reacted positively to Q1 results and pipeline updates.

💰 Q1 2026 revenue reached $389 million, with 80% coming from international markets.

⚖️ GAAP net loss was $1.3 billion due to a $0.9 billion non-recurring litigation settlement charge.

📈 Management reiterated a 2026 plan for up to 10% revenue growth and reduced operating expenses.

✅ EU regulatory approvals were secured for mNEXSPIKE and the flu+COVID combo vaccine mCOMBRIAX.

🔬 A Phase 3 trial for intismeran in high-risk stage 1 NSCLC has officially initiated.

📅 The U.S. PDUFA date for the seasonal flu vaccine candidate is set for August 5, 2026.

🏦 FMR LLC added over 15.7 million shares to its portfolio in Q4 2025.

📉 Insider selling was prominent, with President Stephen Hoge offloading 160,009 shares.

🎯 Analyst price targets range widely from $30.0 to $69.0, with a median of $34.0.

Bullish Signals
  • Q1 revenue hit $389M with 80% from international sales.
  • Management targets reduced GAAP expenses in 2026.
  • EU approved mNEXSPIKE and flu+COVID combo vaccine mCOMBRIAX.
  • Phase 3 intismeran trial launched for NSCLC oncology.
  • Analysts raised price targets after quarterly earnings release.
  • Major investors FMR LLC and Capital World increased holdings.
Risk Factors
  • Q1 GAAP net loss of $1.3 billion.
  • High insider selling by President and CLO.
  • Net institutional outflow: 319 vs 301 investors.
  • Two firms issued 'Underperform' ratings.
Bullish Signals
  • Moderna reported Q1 revenue of $389 million, demonstrating strong international demand that accounts for roughly 80% of total sales.
  • Management has committed to reducing GAAP operating expenses in 2026, excluding the one-time litigation charge, signaling improved operational efficiency.
  • The company achieved significant regulatory milestones with EU approvals for mNEXSPIKE and the flu+COVID combo vaccine mCOMBRIAX.
  • Initiation of the Phase 3 intismeran trial in high-risk stage 1 NSCLC marks a critical step toward potential oncology revenue diversification.
  • Several analysts have lifted price targets following the quarterly release, indicating renewed investor interest in the stock's trajectory.
  • Major institutional investors like FMR LLC and Capital World Investors significantly increased their holdings in Q4 2025.
Risk Factors
  • The company recorded a substantial GAAP net loss of $1.3 billion in Q1, primarily driven by a $0.9 billion non-recurring litigation settlement charge.
  • Insider selling activity has been high over the past six months, with President Stephen Hoge and Chief Legal Officer Shannon Thyme Klinger both executing sales.
  • Institutional ownership is mixed, with 319 investors decreasing their positions in the most recent quarter compared to 301 adding shares.
  • Analyst ratings are divided, with two firms issuing 'Underperform' ratings from Leerink Partners and B of A Securities.
Neutral 0

A Look At Moderna (MRNA) Valuation After Q1 2026 Earnings And New Vaccine Approvals

📈 Q1 2026 revenue surged to $389M, up from $108M last year.

⚠️ Net loss widened to $1.34B due to substantial litigation costs.

💰 Stock trades at $45.37 vs a $175 fair value estimate by analysts.

🧬 Strong pipeline near commercialization requires minimal additional capital investment now.

⚠️ High valuation remains fragile with limited room for trial setbacks.

📈 Moderna reported Q1 2026 revenue of $389 million, representing a significant year-over-year increase from $108 million.

⚠️ The company recorded a wider net loss of $1.343 billion in the quarter, primarily driven by substantial litigation costs.

📉 Stock prices declined over the past month and year, dropping 10.57% in seven days and falling 47.02% year-to-date despite some long-term resilience.

💰 The current stock price of approximately $45.37 is trading well below a "fair value" estimate of $175 suggested by Woodworth Fund analysts.

📉 The valuation gap between the market price and the $175 fair value reflects a belief that the stock may be underpriced relative to its assets.

💡 Moderna reinvested past pandemic profits into new innovations while maintaining a strong balance sheet with relatively low debt levels.

⚖️ Current trading valuations show a Price-to-Sales ratio of 9.3x, which is significantly higher than the estimated fair ratio of 1x and the peer average of 5.4x.

🧬 The company maintains a large pipeline of drug and treatment investments that are close to commercialization without needing additional capital investment.

⚠️ Achieving the high fair value depends heavily on successful commercialization of the pipeline and avoiding significant trial setbacks or extended losses.

🔍 Analysts suggest that the stock's premium valuation is fragile and leaves limited room for error if forecasts take longer than expected to materialize.

🏦 The article notes that government research funding has been defunded, though Moderna remains in a commanding fundamental position despite this shift.

📊 Total shareholder return metrics show mixed signals, with a positive 64% one-year return contrasting with declines over three and five-year periods.

💻 This analysis is provided by Simply Wall St as general commentary based on historical data and does not constitute financial advice to buy or sell the stock.

Bullish Signals
  • Moderna reported Q1 2026 revenue of US$389 million, a significant increase compared to US$108 million a year earlier.
  • The company reinvested its historic pandemic windfall into new innovations while maintaining a pristine balance sheet with relatively low debt.
  • Moderna trades below its book value, indicating potential for significant upside as product investments move closer to commercialization.
  • Analysts' fair value analysis suggests a target price of US$175, which is nearly four times the current trading level of US$45.37.
  • Despite recent litigation costs, the company retains a commanding fundamental position with numerous drug and treatment products in its pipeline.
Risk Factors
  • Moderna reported a wider net loss of US$1.343 billion in Q1 2026 driven by litigation costs, signaling significant financial pressure despite revenue growth.
  • The stock has suffered substantial recent declines, dropping 10.57% over the past 7 days and 47.02% year to date, indicating persistent market weakness.
  • Total shareholder returns have declined over a three-year period by 66.89% and by 72.19% over five years, reflecting poor long-term investor performance.
  • Analysts' average price target sits under the current level of US$45.37, with some estimates suggesting the fair value is lower than the $175 valuation used in bullish narratives.
  • The company faces a potential shortfall of US$2.822b if setbacks occur in clinical trials or if heavy losses continue as predicted in some forecasts.
  • Moderna trades on a P/S ratio of 9.3x, significantly higher than the estimated fair ratio of 1x and peer average of 5.4x, leaving limited room for error in valuation assumptions.
  • The high premium valuation relies heavily on successful commercialization of the pipeline; any delays or failures could lead to a sharp correction as the stock trades below its book value.
Somewhat Bullish +50

Moderna Inc (MRNA) Q1 2026 Earnings Call Highlights: Strategic Growth Amidst Legal Challenges

📈 Q1 revenue hit $400M (up 300% YoY), with UK deliveries fueling growth for spring, fall, and winter campaigns.

💰 Adjusted net loss was $500M after excluding a major $878M one-time litigation settlement cost.

💉 Regulators approved mCOMBRIAX in the EU, marking the first flu plus COVID combo vaccine milestone.

🔬 Oncology pipeline advanced with Phase 3 intismeran trials starting in lung cancer and melanoma.

⚠️ International markets drove 80% of revenue, though analysts warn of future declines from dropping vaccination rates.

📈 Moderna reported Q1 2026 revenue of $400 million, representing a $300 million year-over-year increase driven by strategic partnerships like those with the UK government.

💰 The company posted a net loss of $1.3 billion on a GAAP basis, while excluding a one-time litigation settlement, the adjusted loss was $0.5 billion.

💵 Moderna holds a strong balance sheet with $7.5 billion in cash and investments at the end of Q1 2026.

📉 R&D expenses decreased by 24% year-over-year to $649 million, while SG&A expenses fell 18% to $173 million.

⚖️ A significant portion of costs was driven by a litigation settlement with Arbutus and Genevant totaling $878 million included in the cost of sales.

📅 The full $950 million litigation settlement payment is scheduled for due in Q3 2026.

🌍 Approximately 80% of revenue comes from international markets, with the remaining 20% from the United States.

⚠️ Management issued guidance expecting up to 10% revenue growth for the full year 2026 but noted a potential slowdown in Q2 projections.

💉 Moderna achieved a regulatory milestone with the EU approval of mCOMBRIAX, the first flu plus COVID combo vaccine.

🦠 Spikevax also received approval in the European Union, expected to drive growth in that market starting in 2027.

🏥 The company advanced its oncology pipeline by initiating a Phase 3 clinical trial for intismeran in non-small cell lung cancer with a focus on early-stage disease.

💬 Management clarified that the first quarter's UK delivery was for the spring campaign, with an additional fall campaign planned for Q3 and Q4.

🔬 An interim analysis for the Phase 3 trial of intismeran in adjuvant melanoma is expected to be conducted in 2026 based on event accrual.

⚖️ The CFO stated that a potential additional liability of $1.3 billion related to the 1498 case is not recorded as probable, with resolution possibly occurring in late 2027 or 2028.

📉 Analysts warned of potential future declines in COVID vaccination rates which could negatively impact revenue growth going forward.

Bullish Signals
  • Revenue grew $300 million year-over-year to $400 million in Q1 2026, demonstrating strong commercial traction.
  • R&D expenses decreased by 24% and SG&A expenses dropped 18%, indicating improved operational efficiency despite the net loss.
  • Moderna maintains a robust cash position with $7.5 billion in cash and investments, providing ample liquidity for growth initiatives.
  • The company achieved a strategic milestone with mCOMBRIAX approval in the European Union, opening new market opportunities.
  • Revenue guidance anticipates up to 10% growth for 2026, signaling continued expansion beyond the current quarter.
  • Moderna secured approvals for Spikevax in the European Union, driving expected growth in the EU market for 2027.
  • The Phase 3 clinical trial for intismeran in non-small cell lung cancer has officially begun, diversifying the pipeline into oncology.
  • Management remains optimistic about future outcomes, noting they are "confident" regarding the litigation appeal and see no need to record a charge yet.
  • A second UK delivery campaign is planned for the fall, potentially creating a double year of deliveries and boosting revenue in Q3/Q4.
  • Early-stage disease focus with monotherapy safety profiles looks promising for preventing relapse, opening avenues for potential cures.
  • Phase 2 studies for RCC and muscle invasive bladder cancer are fully enrolled, positioning these assets to move quickly toward registrational studies if data is favorable.
Risk Factors
  • The company reported a significant net loss of $1.3 billion on a GAAP basis in Q1 2026, primarily driven by an $878 million litigation settlement.
  • Moderna faces potential additional liability of up to $1.3 billion if it does not prevail in its appeal regarding the litigation settlement with Arbutus and Genevant.
  • A significant portion of Cost of Sales ($955 million) is attributed to litigation settlements rather than direct product costs, potentially distorting profitability metrics.
  • GuruFocus has detected 4 Warning Signs for MRNA, indicating potential undisclosed risks or financial vulnerabilities.
  • Revenue guidance for Q2 2026 ranges between $50 million and $100 million, representing a substantial deceleration compared to the $400 million generated in Q1 2026.
  • The company anticipates potential future declines in COVID vaccination rates, which poses a direct threat to revenue growth forecasts.
  • Revenue is heavily skewed geographically, with 80% coming from international markets and only 20% from the United States, increasing exposure to foreign exchange and regulatory risks abroad.
  • The resolution timeline for the $1.3 billion litigation charge could extend into late 2027 or 2028, creating prolonged uncertainty over future cash flows.
Somewhat Bearish -42

Moderna in the spotlight: Can pipeline offset earnings decline? - Investing.com

📉 Moderna Q1 earnings due Friday with revenue dropping 63% sequentially to $251M.

💸 Analysts expect a $2.02 EPS loss as Wall Street sentiment turns cautious.

⚠ Stock trades near sell targets while investors await pipeline catalysts and vaccine momentum.

📉 Moderna is set to report Q1 earnings Friday morning after a 63% sequential revenue decline from $678M in Q4.

💸 Analysts forecast a Q1 loss of $2.02 per share on projected revenue of $251.76 million.

📊 Wall Street caution is evident as EPS estimates dropped 36% and revenue estimates fell roughly 5% over the past week.

🏦 The stock trades at $45.72, trading near analyst consensus targets with a majority of ratings holding or recommending sell.

💉 Investors are focused on mRESVIA RSV vaccine momentum, which currently holds 34% market share in the 65+ demographic.

💊 The European Commission's approval of mCOMBRIAX for influenza and COVID-19 represents a key growth driver for the diversified pipeline.

🔬 Melanoma cancer vaccine data showing a 49% reduction in death rates is closely watched as potential Phase 3 catalysts emerge.

🐦 Moderna continues its bird flu vaccine trial with 4,000 participants despite significant loss of federal funding and political headwinds.

🚀 The company aims for up to 10% revenue growth in 2026 and cash breakeven by 2028 following Q1 2025 reporting.

📈 Management faces the challenge of articulating a credible path from $251M quarterly revenue to sustainable profitability.

Bullish Signals
  • Moderna's mRESVIA captured 34% market share in 65+ segment.
  • European Commission approved mCOMBRIAX on April 21 as world's first mRNA combo vaccine for flu and COVID-19.
  • Melanoma vaccine with Merck showed 49% death rate reduction over five years.
  • Bird flu trial enrolling 4,000 participants in late-stage study.
  • Barclays raised Moderna price target to $48 from $25 earlier this month.
  • Company aims for up to 10% revenue growth in 2026 and cash breakeven by 2028.
Risk Factors
  • Revenue drop ~63% amid business model pivot.
  • Analysts project Q1 loss of $2.02 per share.
  • EPS estimates fell 36% in past week.
  • Stock trades at $45.72, 9% above target.
  • Only 3 of 23 analysts rate stock buy.
  • RSV vaccine momentum lacking despite 34% segment share.
  • Bird flu trial proceeds despite funding losses.
  • Cash breakeven goal by 2028 faces hurdles.
Bullish Signals
  • Moderna's mRESVIA RSV vaccine has captured roughly 34% market share in the 65-and-older segment.
  • The European Commission approved mCOMBRIAX on April 21, marking it as the world's first mRNA combination vaccine for influenza and COVID-19.
  • Moderna's melanoma cancer vaccine developed with Merck showed a 49% reduction in death rates over five years in data released in January.
  • Moderna continues to push ahead with its bird flu vaccine trial, enrolling roughly 4,000 participants in a late-stage study.
  • Barclays raised its price target for Moderna to $48 from $25 earlier this month.
  • The company aims to achieve up to 10% revenue growth in 2026 and reach cash breakeven by 2028.
Risk Factors
  • Moderna is facing a sharp sequential revenue drop of approximately 63% as it pivots from its pandemic-era business model to a diversified vaccine franchise.
  • Analysts expect a loss of $2.02 per share on revenue of $251.76 million for the first quarter, indicating continued profitability challenges.
  • Wall Street has grown more cautious with EPS estimates falling 36% over the past week while revenue estimates have declined roughly 5% in the same period.
  • The stock trades at $45.72, implying a downside risk against analyst consensus price targets of $41.42 which suggest roughly 9% downside from current levels.
  • Of the 23 analysts covering the stock, only three rate it a buy while three recommend selling, reflecting significant investor skepticism.
  • Investors are concerned about whether declining COVID vaccine sales can be offset by mRESVIA RSV vaccine which has captured roughly 34% market share in the 65-and-older segment but lacks broader momentum.
  • Moderna is pushing ahead with its bird flu vaccine trial despite losing hundreds of millions in federal funding and facing political headwinds around mRNA technology.
  • The company faces a significant challenge transitioning from a $251 million quarterly revenue run rate to sustainable profitability to achieve its stated goal of reaching cash breakeven by 2028.
Somewhat Bullish +50

BMS vs. Moderna vs. Pfizer: The RNA Platform Race - Pharmaceutical Executive

📉 Pharma competition now focuses on scalable platforms integrating biology, data, and manufacturing for system-based innovation.

💊 Pfizer faces patent cliffs but must choose between partnerships or building full RNA platform control through acquisition.

🧬 BMS acquired Orbital Therapeutics for $1.5B to access circular/linear RNA capabilities while avoiding organic development risks.

⚠ All three firms face execution challenges in integrating research, manufacturing, and clinical development into adaptive engines.

🏆 Winners will be those transforming organizations into true platform-native biopharma entities with continuous learning systems.

📉 Pharma competition is shifting from individual assets to scalable platforms that integrate biology, data science, and manufacturing.

💉 RNA serves as a programmable approach to drug development that accelerates the transition to system-based innovation.

🏆 The core strategic tension now centers on who builds the fastest design–test–learn loops to create structural advantages.

🔬 Moderna is extending its post-COVID identity beyond infectious diseases into oncology, rare diseases, and personalized medicine.

📈 Early signals in Moderna's individualized cancer vaccines are promising, but sustained value depends on translating accumulated learning into diversified revenue.

💊 Pfizer leveraged its BioNTech partnership to dominate the mRNA market during COVID, but now faces patent cliffs and internal capability gaps.

🤝 Pfizer must decide whether to maintain flexibility via partnerships or build full control over RNA platforms through acquisition or integration.

🧬 Bristol Myers Squibb (BMS) is entering the RNA space through acquisition rather than organic development to counter revenue decay from Opdivo's impending patent loss.

💰 BMS acquired Orbital Therapeutics for $1.5 billion to gain access to circular/linear RNA engineering, lipid nanoparticle delivery, and AI-driven design capabilities.

🎯 This deal allows BMS to apply its new RNA platform across autoimmune disease, oncology, and next-generation vaccines without building capability from scratch.

⚠️ All three companies face execution challenges in integrating research, manufacturing, and clinical development into a single adaptive engine.

🔄 The industry standard is now shifting toward companies that can repeatedly produce high-value therapies through continuous learning systems.

🏆 The winners will be those who transform their organization from program-optimizers to true platform-native biopharma entities.

📅 Key timelines and patent cliffs for Opdivo are pressuring BMS to accelerate its RNA portfolio growth within the next decade.

🔍 Executive leadership across all three firms is being evaluated on how effectively they evolve their strategic posture beyond their pandemic-era success.

Bullish Signals
  • Bristol Myers Squibb acquired Orbital Therapeutics for $1.5 billion to gain RNA platform capabilities.
  • The deal adds early-stage therapies in autoimmune disease, oncology, and vaccines to BMS's pipeline.
  • Moderna's years of mRNA innovation created a competitive head start for competitors to match.
  • Moderna's cancer vaccine signals show promise beyond infectious diseases into oncology and rare diseases.
  • Pfizer established a top industry partnership strategy through its collaboration with BioNTech.
  • The Pfizer-BioNTech alliance set benchmarks for speed, scale, and global reach in COVID-19 vaccines.
  • RNA technology rewards integration of biology, data science, and clinical development into adaptive engines.
  • Industry is shifting to scalable platforms with structural advantages for fastest design-test-learn loops.
Risk Factors
  • Moderna must prove platform scalability beyond infectious diseases.
  • Early cancer vaccine signals remain undefined for Moderna.
  • Failure risks Moderna as pandemic outlier versus durable biopharma model.
  • Pfizer benefits from RNA without ownership under revenue normalization.
  • Patent cliff and post-COVID environment challenge Pfizer growth trajectory.
  • Pfizer must choose partnerships or build deeper internal capabilities.
  • BMS needs new growth drivers as Opdivo loses exclusivity near decade end.
  • The $1.5 billion BMS acquisition carries execution risks for RNA integration.
  • BMS accelerated timeline approach may not justify investment quickly.
Bullish Signals
  • Bristol Myers Squibb completed a $1.5 billion acquisition of Orbital Therapeutics to access a proprietary RNA platform combining circular and linear RNA engineering, lipid nanoparticle delivery, and AI-driven design.
  • This acquisition provides BMS with early-stage RNA therapies in autoimmune disease, oncology, and next-generation vaccines, enabling it to reshape its future portfolio as key assets mature.
  • Moderna has accumulated significant years of iteration in mRNA design, delivery, and manufacturing, giving it a head start that is difficult for competitors to replicate quickly.
  • Moderna's early signals in individualized cancer vaccines are showing promise, suggesting the platform can scale beyond infectious disease into oncology and rare diseases.
  • Pfizer established one of the most successful partnership strategies in industry history through its collaboration with BioNTech, producing one of the first approved mRNA vaccines.
  • The Pfizer-BioNTech alliance set a new benchmark for speed, scale, and global reach during the development of COVID-19 vaccines, demonstrating proven execution capabilities.
  • RNA technology represents a programmable approach to drug development that rewards companies for integrating biology, data science, manufacturing, and clinical development into a single adaptive engine.
  • The industry is shifting towards scalable platforms rather than competing solely on individual assets, creating structural advantages for those who build the fastest design–test–learn loops.
Risk Factors
  • Moderna faces pressure to demonstrate its platform can successfully scale beyond infectious diseases into oncology and rare diseases, with early cancer vaccine signals not yet definitive.
  • If Moderna fails to translate its accumulated capability into sustained value, it risks being viewed as a pandemic-era outlier rather than a durable biopharma model.
  • Pfizer faces a complex strategic position as it benefited from the RNA platform without fully owning it, forcing a reassessment under revenue normalization and pipeline pressure.
  • A looming patent cliff and post-COVID environment are challenging Pfizer's growth trajectory, requiring a difficult choice between relying on partnerships or building deeper internal capabilities.
  • Bristol Myers Squibb faces an urgent need to build new growth drivers as key assets like its flagship therapy Opdivo approach loss of exclusivity toward the end of the decade.
  • The $1.5 billion acquisition by BMS is a significant capital outlay that comes with execution risks, as RNA platforms require time for integration and meaningful outputs.
  • BMS faces a critical question on whether its accelerated approach to compressing timelines can deliver learning and value fast enough to justify the investment.
Slightly Bullish +25

Moderna Q1 preview: revenue rebound in focus as losses persist

📅 Moderna reports Q1 earnings before market open on Friday, May 1.

📉 Investors watch for revenue stabilization after the pandemic downturn.

💸 Financial performance has declined since the vaccine windfall ended.

📉 Revenue streams drop as initial demand subsides.

📅 Moderna (MRNA) is scheduled to report first-quarter earnings on Friday, May 1, before market open.

📉 Investors are closely watching for signs of revenue stabilization following a prolonged post-pandemic downturn.

💸 The company has experienced struggling financials since the end of the COVID-19 vaccine windfall era.

📉 Revenue streams have been declining as the initial pandemic-driven demand subsides.

Bullish Signals
  • Moderna reports Q1 earnings Friday May 1 ahead of market open.
  • Results offer opportunity to assess post-pandemic stabilization signs.
  • Upcoming data signals potential revenue rebound inflection point.
Risk Factors
  • Moderna revenue declined post-COVID-19 pandemic.
  • Investors fear prolonged downturn amid earnings.
  • Significant losses persist despite stabilization efforts.
Bullish Signals
  • Moderna is set to report first-quarter earnings on Friday, May 1, ahead of market open, providing an opportunity for investors to assess signs of stabilization following the post-pandemic downturn.
  • The company's upcoming results are closely watched as a key potential inflection point that could signal a revenue rebound.
Risk Factors
  • Moderna continues to struggle following the end of the COVID-19 pandemic, with revenue declining from its previous peak.
  • Investors are concerned about a prolonged post-pandemic downturn as the company faces an earnings report where revenue rebound is in focus.
  • The company persists with significant losses despite attempts to stabilize after the windfall period.